Ipamorelin is a synthetic pentapeptide, a five-amino acid compound, developed as a selective growth hormone secretagogue investigated for its ability to stimulate the release of growth hormone from pituitary gland receptors. Unlike broader growth hormone-releasing compounds, Ipamorelin has been researched for its high selectivity, with studies suggesting it stimulates growth hormone release without meaningfully affecting other hormones such as cortisol or prolactin. This selectivity has made it a subject of interest for researchers investigating growth hormone regulation, body composition signaling, and tissue repair pathway activity in controlled research settings.

GLP3 (RT) is a triple-receptor incretin-based research peptide investigated for its simultaneous activity at the GLP-1, GIP, and glucagon receptors. Extending the dual-agonist framework established by earlier compounds in this class, GLP3 (RT) introduces glucagon receptor co-activation as a third mechanistic dimension, engaging a receptor system with distinct and complementary roles in energy expenditure, hepatic glucose output, and lipid metabolism. As the most recently developed compound in this research class, GLP3 (RT) represents the current frontier of multi-receptor incretin pharmacology and is among the most actively investigated peptides in preclinical metabolic research settings.

GLP2 (TZ) is a dual-receptor incretin-based research peptide investigated for its simultaneous activity at both GLP-1 and GIP receptors. Where earlier compounds in this class engage a single incretin pathway, GLP2 (TZ) is studied for its capacity to activate two complementary receptor systems within a single molecular framework. This dual-agonist architecture has made it a subject of considerable scientific interest, with researchers examining how concurrent GLP-1 and GIP receptor engagement influences metabolic signaling, body composition, glycemic dynamics, and cardiometabolic markers in preclinical research models.

GLP1 (SM) is a long-acting incretin-based research peptide investigated for its role in metabolic regulation, energy intake signaling, and body composition. Structurally optimized for extended half-life, it has become one of the most studied compounds in its class, with a research profile spanning glycemic control, weight regulation, cardiovascular function, and neurological pathway activity. Its sustained receptor engagement makes it a preferred model compound for studying GLP-1 receptor-mediated pathways in preclinical research settings.

GHK-Cu is a naturally occurring copper-binding tripeptide, a small three-amino acid molecule first identified in plasma, saliva, and urine research models, where its levels have been observed to decline over time. This pattern has led researchers to investigate its potential role in the biological signaling processes associated with tissue aging, wound repair, and cellular maintenance. It is one of the most studied peptides in dermatological and regenerative research, with a well-established record in the scientific literature spanning several decades.

Epithalon is a synthetic tetrapeptide, a four-amino acid compound, based on a naturally occurring peptide called epithalamin, which is derived from the pineal gland. It has been studied primarily in the context of aging biology, with research examining its potential to influence telomere length, regulate circadian signaling, and modulate the activity of hormones and growth factors that shift in aging research models. Epithalon is of particular interest to researchers investigating the biological mechanisms of cellular aging, with a notable body of research originating from the St. Petersburg Institute of Bioregulation and Gerontology, where much of the foundational work on this compound was conducted.

CJC-1295 no DAC (also referred to as Modified GRF 1-29) is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the peptide the hypothalamus uses to signal pituitary receptors to release growth hormone. The “no DAC” designation refers to the absence of a Drug Affinity Complex, meaning this version of CJC-1295 has a shorter duration of action than its DAC-containing counterpart, producing growth hormone release pulses that more closely mirror the pulsatile secretion pattern associated with endogenous GHRH receptor activity. It is frequently studied alongside Ipamorelin, with which it works through a complementary receptor mechanism, and has an established research profile in growth hormone biology, body composition signaling, tissue repair, and metabolic regulation.

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of growth hormone (hGH), specifically the amino acid sequence spanning positions 176 to 191 of the hGH molecule. It was developed as a research compound to isolate the fat-metabolizing signaling properties associated with growth hormone without activating the growth-promoting or insulin-sensitizing pathways linked to the full-length hormone. AOD-9604 has been studied primarily for its effects on fat metabolism signaling and body composition, and has also been investigated for cartilage repair and regenerative signaling properties in preclinical research models.